- Home
- ALDX vs DMF Comparison
ALDX vs DMF Comparison
Compare ALDX & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- DMF
- Stock Information
- Founded
- ALDX 2004
- DMF 1988
- Country
- ALDX United States
- DMF United States
- Employees
- ALDX N/A
- DMF N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- DMF Finance/Investors Services
- Sector
- ALDX Health Care
- DMF Finance
- Exchange
- ALDX Nasdaq
- DMF Nasdaq
- Market Cap
- ALDX 133.7M
- DMF 152.2M
- IPO Year
- ALDX 2014
- DMF N/A
- Fundamental
- Price
- ALDX $2.17
- DMF $6.94
- Analyst Decision
- ALDX Strong Buy
- DMF
- Analyst Count
- ALDX 2
- DMF 0
- Target Price
- ALDX $9.50
- DMF N/A
- AVG Volume (30 Days)
- ALDX 1.2M
- DMF 60.7K
- Earning Date
- ALDX 05-14-2025
- DMF 01-01-0001
- Dividend Yield
- ALDX N/A
- DMF 2.66%
- EPS Growth
- ALDX N/A
- DMF N/A
- EPS
- ALDX N/A
- DMF 0.15
- Revenue
- ALDX N/A
- DMF N/A
- Revenue This Year
- ALDX N/A
- DMF N/A
- Revenue Next Year
- ALDX N/A
- DMF N/A
- P/E Ratio
- ALDX N/A
- DMF $45.13
- Revenue Growth
- ALDX N/A
- DMF N/A
- 52 Week Low
- ALDX $1.14
- DMF $5.37
- 52 Week High
- ALDX $7.20
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- ALDX 38.93
- DMF 49.38
- Support Level
- ALDX $2.10
- DMF $6.84
- Resistance Level
- ALDX $2.30
- DMF $7.06
- Average True Range (ATR)
- ALDX 0.15
- DMF 0.06
- MACD
- ALDX 0.06
- DMF 0.00
- Stochastic Oscillator
- ALDX 37.93
- DMF 57.12
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.